HODGKIN LYMPHOMA

This study tests whether combining the drug pembrolizumab with a precise form of radiation can cure people whose Hodgkin lymphoma has returned or not responded to initial treatment. The trial includes 22 adults with early-stage disease. The goal is to achieve a complete response …

This study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…

This early-phase study tests whether giving healthy donor natural killer (NK) cells along with two drugs (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach/esophageal, or blood cancers. The NK cells are meant to attack cance…

This study tests a combination of four drugs (brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine) in 25 people with untreated advanced Hodgkin lymphoma. The goal is to see if this approach can control the disease while reducing side effects. Participants have stage …

This study tests whether adding a drug called cyclophosphamide after a stem cell transplant can reduce the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers who are…

This study tests a shorter course of chemotherapy (Stanford V) for children and young adults with a favorable type of Hodgkin lymphoma. Those who still have signs of cancer after chemo may also get low-dose radiation to the affected area. The goal is to see if this approach can i…

This study tests a new drug called tislelizumab combined with chemotherapy for people whose Hodgkin lymphoma has returned or not responded to first treatment. The goal is to see if this approach works as well as the standard intensive chemo and stem cell transplant. About 75 adul…

This study tests a new way to grow stem cells from umbilical cord blood to help people with high-risk blood cancers like leukemia and lymphoma recover faster after a bone marrow transplant. About 22 patients will receive the expanded stem cells along with standard chemotherapy an…

This study looks at adding pembrolizumab (an immunotherapy drug) to standard chemotherapy for children and young adults newly diagnosed with classical Hodgkin lymphoma whose cancer didn't shrink enough after initial chemo. About 340 participants will receive this combination to s…

This study tests whether adding special 'veto' cells to a stem cell transplant can help donor cells grow in the body without causing severe graft-versus-host disease (GVHD). It includes 16 people aged 12-75 with various blood cancers or bone marrow failure. The veto cells are tre…

This study tests a vaccine called Triplex to see if it can prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be dangerous for people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA…

This study tests a treatment plan from the U.S. on 200 Chinese children and teens with newly diagnosed Hodgkin lymphoma. The goal is to see if it works as well in China, where the disease is rare and treatment options are limited. Researchers will track how long patients stay can…

This study tests two immune-boosting drugs, ipilimumab and nivolumab, in people with classic Hodgkin lymphoma that has returned or not responded to prior therapy. The goal is to see if these drugs can shrink tumors when given alone or together. The trial enrolled 13 adults with m…

This study tests two immunotherapy drugs, cobolimab and dostarlimab, together in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The …

This study tests whether adding the drug nivolumab to standard chemotherapy (ABVD) can improve the chance of cure for people with high-risk Hodgkin lymphoma. About 82 participants with untreated stage III or IV disease will receive the combination. The goal is to see if the new a…

This early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…

This study is for children and young adults up to age 21 with high-risk blood cancers like leukemia or lymphoma. It tests a transplant using specially treated donor cells from a family member to reduce the risk of the cancer coming back while lowering the chance of a serious side…

This study tests a combination of two drugs, nivolumab and axatilimab, in adults with classical Hodgkin lymphoma that has returned or not responded to prior treatments, including anti-PD-1 therapy. The main goal is to see how well the combination shrinks or controls the cancer. N…

This study tests whether giving different chemotherapy combinations based on a patient's risk level can improve outcomes for children and young adults with Hodgkin lymphoma. About 232 participants will receive one of three treatment plans, with radiation only if needed. The goal …

This study looks at whether a special PET scan using a natural amino acid called methionine can help doctors see tumors in children and young adults with cancer. About 500 participants will get the scan to check if it can find tumors at diagnosis and tell the difference between a…

This early-phase trial tests whether giving a CMV vaccine to stem cell donors can boost the recipient's immunity after transplant. About 34 blood cancer patients receiving donor stem cells are involved. The goal is to prevent CMV viremia, a common and serious viral infection, wit…

This study tests a new approach to help childhood cancer survivors who struggle with memory, attention, and thinking after their treatment. Participants use a special light device on their head (called transcranial photobiomodulation) at home while doing computer brain games. The…

This study tests whether giving radiation over a shorter time (instead of the usual 5-6 weeks) is safe for people with lymphoma that has returned or not responded to treatment. About 30 participants will receive different shortened radiation doses to find the safest one. The goal…

This study looks at how common obstructive sleep apnea is in adults who survived Hodgkin lymphoma after chest radiation. Researchers will compare 220 survivors to similar people without cancer to see if radiation increases sleep apnea risk. They also want to find links between sl…

This study follows over 1,500 young adults who survived childhood cancers like leukemia, brain tumors, and Hodgkin lymphoma. Researchers measure physical frailty—a set of five fitness tests—over five years to see if it predicts future health problems. The goal is to identify surv…

This study looks at whether a blood test (liquid biopsy) can predict if lymphoma will come back within 1-2 years after finishing first treatment. It involves 108 adults with B-cell or Hodgkin lymphoma. The goal is to see if this test works as well as or better than the standard P…

This study is testing a new system that combines aging, mental health, and social needs checks for cancer patients aged 65 and older. The goal is to help doctors provide care that fits each patient's life. About 35 people with different cancers will try it during their first visi…

This study looks at medical records from 400 older adults (age 60+) with Hodgkin lymphoma in China. Researchers are collecting information on patient characteristics, treatments, and outcomes to build a model that helps predict how the disease will progress. The goal is to help d…

This study follows 350 stem cell transplant survivors to see how their heart, lungs, and muscles work together over two years. Researchers measure exercise capacity and other health markers to learn why transplant survivors have a higher risk of heart disease. Participants includ…